Reference
- Vanky F, Gorsky T, Masucci M G, Klein E. Lysis of tumour biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. J Exp Med 1982; 155: 83–95
- Vose B M, Bonnard GD. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin-2. Int J Cancer 1982; 29: 33–9
- Ichino Y, Ishikawa T. Generation of human cytotoxic T lymphocytes against fresh autologous and allogeneic solid tumors by mixed lymphocyte tumor cell culture with T cell growth factor. Gann 1984; 75: 436–41
- Rosenberg S A, Lotze M T, Muul LM. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 1985; 313: 1485–92
- Rosenberg S A, Spiess P, Lefrenieve R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocyte. Science 1986; 233: 1318–21
- Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J Immunol 1986; 136: 3891–6
- Ikawa T, Ishikawa T, Eura M. Study of head and neck cancer treatment by administration of autologous cytotoxic T lymphocyte induced by stimulation with tumor cell. II. Induction of killer cells by stimulation with allogeneic tumor cell. J Otolaryngol Jpn 1988; 91: 2079–81
- Maehara T, Eura M, Ikawa T, Ishikawa T. Differences of sensitivity to autologous cytotoxic lymphocytes between primary tumor and its cervical lymph node metastases. Auris Nasus Larynx 1987; 14: 187–98
- Fujimoto S, Green M I, Sehon AH. Regulation for the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts. J Immunol 1976; 116: 800–6
- Eura M, Maehara T, Ikawa T, Ishikawa T. Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients. Cancer Immunol Immunother 1988; 27: 147–53